Raith GmbH

Zum Unternehmen

Raith ist ein weltweit führender Entwickler und Hersteller von Nanofabrikationssystemen und -software zur Herstellung und Analyse von Strukturen im Nanobereich.

Seit 1980 entwickelt, fertigt und vertreibt Raith Systemlösungen für F&E Applikationen zur Analyse und Strukturierung von Mikrochip-Leiterbahnen und anderen Nanostrukturen, z.B. im Bereich der Biochemie oder Cybersecurity. Raiths weltweite Kundenbasis umfasst führende Universitäten, Forschungszentren und Forschungsabteilungen großer Technologieunternehmen.

Raith verfügt über zwei Produktionsstandorte in Deutschland und Holland, sowie drei Vertriebseinheiten in den USA, China und Indien. Darüber hinaus wird Raith in 15 Ländern durch Vertriebspartner repräsentiert. Weltweit beschäftigt Raith rund 200 Mitarbeiter, davon 120 am Hauptsitz in Dortmund, und generierte im Geschäftsjahr 2015 einen Umsatz in Höhe von € 54 Mio.

Zur Transaktion

capiton erwirbt die Raith GmbH vom Eigenkapitalpartner HANNOVER Finanz, der das Unternehmen seit 2002 beim Wachstum und Zukäufen begleitete, und wird zukünftig mehrheitlich an Raith beteiligt sein. Die Finanzierung der Transaktion erfolgt aus Mitteln des Fonds capiton V sowie durch Bankdarlehen.

capiton plant weiteres organisches Wachstum auf Basis der starken Marktpositionierung sowohl international als auch durch neue Produkteinführungen. Außerdem hat capiton weitere Mittel im Fonds capiton V für gezielte Übernahmen reserviert.

Die Transaktion steht noch unter dem Vorbehalt der Genehmigung der Kartellbehörden. Über den Kaufpreis haben Käufer und Verkäufer Stillschweigen vereinbart.

capiton wurde bei dieser Transaktion von Roland Berger (Commercial), Ernst & Young (Financial, Steuern), BMH (Legal) sowie Tauw (ESG) beraten.

Pressemitteilungen

capiton portfolio company Wundex is pleased to announce the acquisition of ELLIPSA, a wound care specialist with headquarters in Regensburg (Bavaria) and a second center of operations in Munich. In addition to the provision of wound care services and the wholesale supply of medical products, ELLIPSA has developed a proprietary digital education and training platform […]

capiton portfolio company Cedes is proud to announce the acquisition of the Vitector portfolio from Fraba, securing a leading position in the industrial door sensor market. As a global leader in elevator sensors, Cedes successfully applied its technology expertise and power of innovation to gain a foothold in the industrial door market, providing ultra-reliable safeguarding […]

Asyril SA, headquartered in Villaz-St-Pierre in Switzerland with subsidiaries in the US and Japan, is a market and technology leader in the flexible part feeder market. Its products are being used globally in assembly lines, facilitating process automation for a variety of industries.   Asyril’s product portfolio covers flexible feeding systems based on a patented […]

AlphaPet Ventures has started to implement its international expansion strategy with the acquisition of Arden Grange, a leading UK brand in the premium dog food segment. Family-run Arden Grange pioneered the category of species-appropriate dog food in the UK more than 25 years ago. Customers appreciate especially the high quality of the products, which aim […]

We are delighted to announce the successful acquisition of Stuga Machinery by our portfolio company Stürtz Group.   Stuga Machinery Limited, a market leading manufacturer of PVC sawing and machining centres to the UK and Ireland windows and doors industry, has been acquired by Stürtz Group. All of Stuga’s Directors and staff are continuing with […]

We are delighted to announce that our portfolio company EVP Group is combining forces with Vitafy Brands. Founded in Munich in 2014, Vitafy Brands has grown to be a leading consumer health D2C online platform for its own brands focusing on the development and offering of functional Consumer Health OTC products for health focused customers. […]

capiton acquires a majority stake in the Betonbau Group alongside its experienced management team, Mr. Volker Ernst and Mr. Thomas Sachers, from the SCHWENK Group in a carve-out transaction. Betonbau Group, headquartered in Waghäusel, Germany, was established in 1963. The name “Betonbau” goes back to its foundations when the company focused on the production of […]

capiton successfully closes fund VI at €504 million Largest fund in the company’s history Approximately €260 million, including co-investment, already deployed in seven portfolio companies Fund to continue successful deployment in capiton’s focus sectors Pharmaceuticals, Medical Technology, Industrial Technology and Responsible Consumption   Berlin, 24 November 2021 – capiton AG (“capiton”), a leading owner-managed private […]

capiton acquires a stake in Solvis, a sustainable heating pioneer, backing the members of the management team which remain significant shareholders in the company. Solvis is headquartered in Braunschweig, Germany. The company was founded in 1982 and retains its operations in a factory which has been inaugurated as the first zero-emission-facility in Germany in 2002. […]

BIOGGIO, SWITZERLAND – October 4, 2021 – The KD Pharma Group has acquired a 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids, such as Cannabidiol (CBD) in a highly-purified form. “Trigal has successfully and profitably grown by being a first mover in the API market for […]

capiton acquires the majority stake in Kutterer Mauer AG, backing one of the founders, Mr. Mauer in continuing the growth story of the company. Mr. Mauer as well as other management members invest alongside capiton. Kutterer Mauer AG is a globally operating manufacturer of caps and closure solutions with >450 employees. The Group designs and […]

capiton has successfully closed a new top-up single-asset fund for its fast-growing portfolio company KD Pharma Group („KD Pharma“). This top-up fund will provide KD Pharma with the equity financing for a number of additional strategic investments, in particular add-on acquisitions as well as organic growth initiatives to transfer KD Pharma‘s unique technology and service […]